ATE413183T1 - Verwendung von laminarin in der behandlung von krebs - Google Patents

Verwendung von laminarin in der behandlung von krebs

Info

Publication number: ATE413183T1
Authority: AT; Austria
Prior art keywords: cancer; treatment; laminarin; cancers; immunostimulant
Prior art date: 2001-11-30

Application number

AT02787872T

Other languages

English (en)

Inventor

Jean-Claude Yvin

Vaclav Vetvicka

Original Assignee

Goemar Lab Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-30

Filing date

2002-11-29

Publication date

2008-11-15

2002-11-29 Application filed by Goemar Lab Sa filed Critical Goemar Lab Sa

2008-11-15 Application granted granted Critical

2008-11-15 Publication of ATE413183T1 publication Critical patent/ATE413183T1/de

Links

206010028980 Neoplasm Diseases 0.000 title abstract 4
DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 title abstract 2
229920001543 Laminarin Polymers 0.000 title abstract 2
239000005717 Laminarin Substances 0.000 title abstract 2
201000011510 cancer Diseases 0.000 title abstract 2
208000035143 Bacterial infection Diseases 0.000 abstract 1
206010006187 Breast cancer Diseases 0.000 abstract 1
208000026310 Breast neoplasm Diseases 0.000 abstract 1
241000282414 Homo sapiens Species 0.000 abstract 1
206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
241001465754 Metazoa Species 0.000 abstract 1
208000031888 Mycoses Diseases 0.000 abstract 1
208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
230000001580 bacterial effect Effects 0.000 abstract 1
239000008280 blood Substances 0.000 abstract 1
208000029742 colonic neoplasm Diseases 0.000 abstract 1
230000007812 deficiency Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
206010017758 gastric cancer Diseases 0.000 abstract 1
229960001438 immunostimulant agent Drugs 0.000 abstract 1
239000003022 immunostimulating agent Substances 0.000 abstract 1
230000003308 immunostimulating effect Effects 0.000 abstract 1
201000002313 intestinal cancer Diseases 0.000 abstract 1
210000000936 intestine Anatomy 0.000 abstract 1
201000005202 lung cancer Diseases 0.000 abstract 1
208000020816 lung neoplasm Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
201000011549 stomach cancer Diseases 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
230000003612 virological effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Natural Medicines & Medicinal Plants (AREA)
Biotechnology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Botany (AREA)
Microbiology (AREA)
Mycology (AREA)
Medical Informatics (AREA)
Alternative & Traditional Medicine (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Transplantation (AREA)
Virology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT02787872T 2001-11-30 2002-11-29 Verwendung von laminarin in der behandlung von krebs ATE413183T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/999,202 US6660722B2 (en)	2001-11-30	2001-11-30	Therapeutical treatments

Publications (1)

Publication Number	Publication Date
ATE413183T1 true ATE413183T1 (de)	2008-11-15

Family

ID=25546011

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02787872T ATE413183T1 (de)	2001-11-30	2002-11-29	Verwendung von laminarin in der behandlung von krebs

Country Status (11)

Country	Link
US (1)	US6660722B2 (de)
EP (1)	EP1448215B1 (de)
JP (1)	JP4633361B2 (de)
KR (1)	KR20040096498A (de)
CN (1)	CN100558369C (de)
AT (1)	ATE413183T1 (de)
AU (1)	AU2002352187A1 (de)
CA (1)	CA2468314C (de)
DE (1)	DE60229767D1 (de)
RU (1)	RU2004119854A (de)
WO (1)	WO2003045414A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7671040B2 (en) *	2003-09-23	2010-03-02	Laboratoires Goemar S.A.	Chemotherapeutic antineoplastic treatment
US7070778B2 (en)	2003-10-30	2006-07-04	Laboratoire Goemar Sa	Therapeutical combination against cancer
US20050220846A1 (en)	2004-04-05	2005-10-06	Puntenney Steven B	Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function
CA2609098C (fr) *	2005-05-18	2012-07-10	Laboratoires Goemar	Nouvel ingredient alimentaire et produits le contenant
FR2885812B1 (fr) *	2005-05-18	2007-07-27	Goemar Lab Sa	Medicament a base de laminarine ou d'oligolaminarines pour le traitement de la septicemie et du choc septique
FR2885811B1 (fr) *	2005-05-18	2007-08-10	Goemar Lab Sa	Medicament a base de laminarine ou d'oligolaminarines pour le traitement des hepatites virales
DE602006009144D1 (de) *	2005-11-21	2009-10-22	Bioatlantis Ltd	Zusammensetzungen für die verbesserung der darmgesundheit und der tierischen leistung enthaltend beta-glucans and alfa-fucans
FR2899815B1 (fr) *	2006-04-14	2008-07-11	Goemar Lab Sa	Nouveaux medicaments pour les traitements contre les retrovirus
FR2909553B1 (fr) *	2006-12-08	2009-03-06	Bio Serae Lab	Oligo-b(1-3)-glucanes a effet inhibiteur des reactions allergiques,et applications.
FR2910322B1 (fr) *	2006-12-22	2009-10-30	Mer Soc Par Actions Simplifiee	Utilisation d'oligo-b-(1,3)-glucanes modifies pour le traite traitement de maladies du systeme immunitaire, oligo-b-(1,3) glucane-(1,3)-mannose, oligo-b-(1,3)-glucane-(1,3)-mannitol et leurs derives, ...
NL1036661C2 (en) *	2009-03-04	2010-09-07	Serrix B V	Anti-fungal compounds & compositions.
BRPI1011211A8 (pt) *	2009-05-21	2018-01-02	Bioatlantis Ltd	aprimoramento da saúde gastrointestinal, imunidade e desempenho pela intervenção na dieta
JP5968643B2 (ja) *	2012-02-22	2016-08-10	日本メナード化粧品株式会社	メラノサイト分化誘導抑制剤
EP3295795A1 (de)	2013-03-20	2018-03-21	Bioatlantis Limited	Verwendung einer nichtnematiziden zusammensetzung
EP3110437B1 (de)	2014-02-12	2017-11-29	Omnigen Research, LLC	Zusammensetzung und verfahren zur förderung der reduktion von hitzestress bei tieren
LT6145B (lt)	2014-04-14	2015-04-27	Uab "Biocentras"	TERAPINĖ ß-GLIUKANŲ KOMPOZICIJA, MODULIUOJANTI ŽMOGAUS IMUNINĘ SISTEMĄ IR INICIJUOJANTI VĖŽINIŲ LĄSTELIŲ ARDYMĄ
CN105147732A (zh) *	2015-10-26	2015-12-16	北京百生康生物科技有限公司	鳄鱼血多糖在乳腺癌治疗中的应用
CN111544592B (zh) *	2020-03-13	2022-05-03	中山大学附属第一医院	模式识别受体Dectin-1抑制剂对受体移植物的免疫保护及诱导免疫耐受的应用
WO2023002252A1 (en)	2021-07-21	2023-01-26	Bioatlantis Limited	Composition comprising beta-glucans and alpha-fucans for improving gut health and animal performance and methods of making the same
US20250057873A1 (en) *	2021-12-16	2025-02-20	Tokyo University Of Science Foundation	Intestinal Tumor Suppressor, PGE2 Production Inhibitor, and IL-22BP Production Promoter
WO2025138017A1 (zh) *	2023-12-28	2025-07-03	清华大学	昆布及其活性成分在制备治疗高果糖促进的结肠炎相关结直肠癌的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0742234B2 (ja) *	1989-02-10	1995-05-10	株式会社紀文食品	逆転写酵素阻害剤
IL108951A0 (en) *	1994-03-13	1994-06-24	Hadasit Med Res Service	Pharmaceutical compositions containing polysulfated polysaccharides
JP2002012552A (ja) *	2000-04-27	2002-01-15	Okamoto Denki Kk	動物・ヒト用免疫賦活調整剤及び動物・ヒトの感染症や皮膚病、癌の予防・治療方法
FR2816213B1 (fr) *	2000-11-03	2005-04-22	Goemar Lab Sa	Medicament anti-inflammatoire et cicatrisant

2001
- 2001-11-30 US US09/999,202 patent/US6660722B2/en not_active Expired - Fee Related
2002
- 2002-11-29 AT AT02787872T patent/ATE413183T1/de not_active IP Right Cessation
- 2002-11-29 AU AU2002352187A patent/AU2002352187A1/en not_active Abandoned
- 2002-11-29 JP JP2003546915A patent/JP4633361B2/ja not_active Expired - Fee Related
- 2002-11-29 RU RU2004119854/14A patent/RU2004119854A/ru not_active Application Discontinuation
- 2002-11-29 KR KR10-2004-7008211A patent/KR20040096498A/ko not_active Withdrawn
- 2002-11-29 DE DE60229767T patent/DE60229767D1/de not_active Expired - Lifetime
- 2002-11-29 CN CNB028236548A patent/CN100558369C/zh not_active Expired - Fee Related
- 2002-11-29 WO PCT/EP2002/013512 patent/WO2003045414A2/en not_active Ceased
- 2002-11-29 EP EP02787872A patent/EP1448215B1/de not_active Expired - Lifetime
- 2002-11-29 CA CA2468314A patent/CA2468314C/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE60229767D1 (de)	2008-12-18
WO2003045414A3 (en)	2003-10-16
US6660722B2 (en)	2003-12-09
JP4633361B2 (ja)	2011-02-16
KR20040096498A (ko)	2004-11-16
EP1448215B1 (de)	2008-11-05
AU2002352187A1 (en)	2003-06-10
EP1448215A2 (de)	2004-08-25
US20030119780A1 (en)	2003-06-26
CN1596118A (zh)	2005-03-16
JP2005510543A (ja)	2005-04-21
WO2003045414A2 (en)	2003-06-05
CA2468314C (en)	2010-10-19
AU2002352187A8 (en)	2003-06-10
CN100558369C (zh)	2009-11-11
CA2468314A1 (en)	2003-06-05
RU2004119854A (ru)	2005-03-27

Legal Events

Date	Code	Title	Description
2009-05-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60229767D1 (de)	2008-12-18	Verwendung von laminarin in der behandlung von krebs
CY1122817T1 (el)	2021-05-05	Νεα αντι-il 13 αντισωματα και χρησεις αυτων
ATE341550T1 (de)	2006-10-15	Quinolinyl-pyrrolopyrazole
CY1107838T1 (el)	2013-06-19	Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
CY1105552T1 (el)	2010-07-28	Βαλπροϊκο οξυ και παραγωγα για την συνδυαστικη θεραπευτικη αντιμετωπιση ανθρωπινων καρκινων και για την αντιμετωπιση της μεταστασης ογκων και ελαχιστης υπολειμματικης νοσου
CY1108629T1 (el)	2014-04-09	Συνδυασμος ετ 743 με 5 φθοριοουρακιλο προ-φαρμακα δια την θεραπευτικη αγωγη του καρκικου
EA200300544A1 (ru)	2003-08-28	Эффективные противоопухолевые лекарственные средства
CY1108765T1 (el)	2014-04-09	ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
BR0112591A (pt)	2003-07-22	Derivados de acridina e sua aplicação como medicamento
NO20022065L (no)	2002-06-24	Terapeutisk anvendelse
BRPI0601736A (pt)	2007-05-15	métodos de terapia adjuvante, método de cura de cáncer de mama não metastático, método de redução de reincidência de doenças, método de instrução de pacientes humanos com cáncer de mama her2-positivo não metastático, método de produção e métodos comerciais
EP1706423B8 (de)	2009-07-08	Therapeutische und diagnostische anti-hsp 70-antikörper
MX2025005779A (es)	2025-07-01	Conjugado de anticuerpo-farmaco, metodo de preparacion y uso del mismo
SE0300098D0 (sv)	2003-01-15	Use of cyclin D1 inhibitors
WO2005027936A3 (en)	2005-07-28	Pharmaceutical compositions and therapeutical treatment with oligo-beta-(1, 3)-glucans
DE60311788D1 (de)	2007-03-29	Kombinationstherapie zur behandlung von krebs
DE60041974D1 (de)	2009-05-20	5-methylindirubin zur verwendung in der behandlung von menschlichen festen tumoren
DE60116075D1 (de)	2006-01-26	Behandlung von tumoren mit photodynamischer therapie
ATE461713T1 (de)	2010-04-15	Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren
ATE345805T1 (de)	2006-12-15	Calciumtrifluoracetat mit zytotoxischer wirkung
AU2003229876A1 (en)	2003-10-13	Tumour associated antigens
DK0455769T3 (da)	1996-02-05	Anvendelse af 7-OH-1,2-benzopyron til fremstilling af et lægemiddel til behandling af magline tumore r hos mennesker
RU2001106336A (ru)	2001-09-20	Способ комбинированного лечения рака пищевода грудного отдела
EA200600987A1 (ru)	2006-10-27	Применение сирамезина в лечении злокачественных опухолей
UA20727A (uk)	1997-10-07	Спосіб лікуваhhя раку легеhі шляхом хіміоімуhотерапії